ILLUMINA VENTURES

ILLUMINA VENTURES

Portfolio Spotlight

Pattern Logo_black_RGB.jpg

Revolutionizing bacterial diagnosis to fight antibiotic resistance

October 2020 - “Pattern’s next-gen clinical microbiology platform will set new standards in antibiotic susceptibility testing,” said Nick Naclerio, Ph.D., Founding Partner at Illumina Ventures. “By measuring phenotypic bacterial response at single-cell resolution, Pattern is meeting the challenge of antibiotic resistance with an innovative platform that is poised to revolutionize bacterial diagnosis.”  

Imagine How Genomics Will Transform Our Future.
 

Copyright 2020 IIF Management Company LLC.  All rights reserved.  “Illumina” and “Illumina Ventures” are trademarks of Illumina, Inc. and are used herein with their permission.  All other company names, logos, and other trademarks are the property of their respective owners.